FEROZ Stock Overview
Engages in the importing, manufacturing, and sale of pharmaceutical products and medical devices in Pakistan, Afghanistan, Sri Lanka, the Philippines, Kenya, Myanmar, Kyrgyzstan, Mongolia, Cambodia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Ferozsons Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨309.65 |
| 52 Week High | PK₨393.00 |
| 52 Week Low | PK₨217.90 |
| Beta | 0.55 |
| 1 Month Change | -9.73% |
| 3 Month Change | -4.81% |
| 1 Year Change | 40.65% |
| 3 Year Change | 19.99% |
| 5 Year Change | 176.89% |
| Change since IPO | 14,549.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| FEROZ | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | -0.09% | 1.1% | 2.0% |
| 1Y | 40.7% | 163.4% | 58.0% |
Return vs Industry: FEROZ underperformed the PK Pharmaceuticals industry which returned 163.4% over the past year.
Return vs Market: FEROZ underperformed the PK Market which returned 58% over the past year.
Price Volatility
| FEROZ volatility | |
|---|---|
| FEROZ Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in PK Market | 8.2% |
| 10% least volatile stocks in PK Market | 3.5% |
Stable Share Price: FEROZ has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: FEROZ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 1,896 | Osman Waheed | ferozsons-labs.com |
Ferozsons Laboratories Limited, together with its subsidiaries, engages in the importing, manufacturing, and sale of pharmaceutical products and medical devices in Pakistan, Afghanistan, Sri Lanka, the Philippines, Kenya, Myanmar, Kyrgyzstan, Mongolia, Cambodia, and internationally. The company offers products in various therapeutic areas of anti-fungal, anti-viral, antibiotics, cardiometabolic, cough, dermatology, diabetes, gastrointestinal and liver, oncology, orthopedic, and urology and nephrology areas. It also provides medical devices in the areas of cardiology, G.I. endoscopy, oncology, peripheral vascular disease, urology, and women's health applications.
Ferozsons Laboratories Limited Fundamentals Summary
| FEROZ fundamental statistics | |
|---|---|
| Market cap | PK₨13.46b |
| Earnings (TTM) | PK₨689.01m |
| Revenue (TTM) | PK₨16.82b |
19.5x
P/E Ratio0.8x
P/S RatioIs FEROZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FEROZ income statement (TTM) | |
|---|---|
| Revenue | PK₨16.82b |
| Cost of Revenue | PK₨9.63b |
| Gross Profit | PK₨7.18b |
| Other Expenses | PK₨6.50b |
| Earnings | PK₨689.01m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.85 |
| Gross Margin | 42.73% |
| Net Profit Margin | 4.10% |
| Debt/Equity Ratio | 50.0% |
How did FEROZ perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield19%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/22 19:31 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ferozsons Laboratories Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Insight Securities (Private) Limited |
| Naima Ali | Shajar Capital Pakistan (Private) Limited |